Inceptionr LLC Invests $426,000 in Arrowhead Pharmaceuticals, Inc. $ARWR

Inceptionr LLC purchased a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 6,791 shares of the biotechnology company’s stock, valued at approximately $426,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Arrowstreet Capital Limited Partnership boosted its stake in Arrowhead Pharmaceuticals by 3,142.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after acquiring an additional 2,017,489 shares during the last quarter. Norges Bank bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $113,159,000. Fred Alger Management LLC raised its position in shares of Arrowhead Pharmaceuticals by 497.4% during the 4th quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company’s stock valued at $121,693,000 after acquiring an additional 1,526,164 shares during the last quarter. Deerfield Management Company L.P. acquired a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter valued at $34,249,000. Finally, Vestal Point Capital LP acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $59,751,000. 62.61% of the stock is owned by institutional investors.

Analysts Set New Price Targets

ARWR has been the subject of a number of analyst reports. Stifel Nicolaus started coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They set a “buy” rating and a $98.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Sanford C. Bernstein upped their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Leerink Partners increased their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research report on Wednesday, June 17th. Finally, Morgan Stanley lifted their price objective on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.83.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the transaction, the director owned 52,012 shares of the company’s stock, valued at approximately $3,998,682.56. The trade was a 5.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock opened at $85.60 on Monday. The company has a market capitalization of $12.06 billion, a P/E ratio of -39.81 and a beta of 1.26. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23. The business has a 50-day moving average of $77.94 and a two-hundred day moving average of $70.02. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $15.01 and a 1 year high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The business had revenue of $73.74 million for the quarter, compared to analysts’ expectations of $73.84 million. During the same quarter in the previous year, the business posted $2.75 EPS. Arrowhead Pharmaceuticals’s revenue for the quarter was down 86.4% on a year-over-year basis. As a group, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -3.08 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.